| Dec 31,
2016 | Dec 31,
2017 | Dec 31,
2018 | Dec 31,
2019 | Dec 31,
2020 | Dec 31,
2021 | Dec 31,
2022 | Dec 31,
2023 | Dec 31,
2024 |
|---|
| Net loss | -119 | -93 | -674 | -949 | -1,597 | -1,413 | -2,004 | -882 | -645 |
|---|
| Depreciation and amortization expense | - | 5 | 10 | 19 | 32 | 46 | 66 | 88 | 172 |
|---|
| Share-based compensation expense | 11 | 43 | 87 | 134 | 183 | 241 | 303 | 368 | 442 |
|---|
| Acquired in-process research and development | - | - | - | 69 | - | - | - | 47 | 60 |
|---|
| Amortization of Research And Development Financing Liability | - | - | - | - | -114 | -112 | -96 | -55 | -73 |
|---|
| Unrealized losses on long-term investments | - | - | - | - | - | - | - | - | -24 |
|---|
| Deferred income tax expense | -1 | -6 | -22 | -9 | -28 | -41 | 2 | 1 | 26 |
|---|
| Gain on BMS termination settlement | - | - | - | - | - | - | - | 363 | - |
|---|
| Other items, net | - | - | - | -9 | 7 | 24 | 9 | -6 | 11 |
|---|
| Accounts receivable | - | 29 | 12 | 30 | -10 | 423 | -304 | 188 | 329 |
|---|
| Inventories | - | 11 | 5 | 12 | 59 | 153 | 57 | 141 | 91 |
|---|
| Other assets | - | - | - | - | - | 107 | 3 | -12 | -45 |
|---|
| Accounts payable | 3 | 55 | 23 | 2 | 96 | 20 | -4 | 21 | 121 |
|---|
| Accrued expenses and other payables | 14 | 25 | 51 | 64 | 183 | 140 | 46 | 180 | 111 |
|---|
| Deferred revenue | - | - | - | -28 | - | 408 | -152 | -256 | 1 |
|---|
| Other liabilities | - | - | - | - | - | - | -1 | 1 | -15 |
|---|
| Net cash used in operating activities | - | 13 | -548 | -750 | -1,283 | -1,299 | -1,497 | -1,157 | -141 |
|---|
| Purchases of property and equipment | 24 | 46 | 70 | 90 | 118 | 263 | 325 | 562 | 493 |
|---|
| Proceeds from sale or maturity of short-term investments | 184 | 424 | 2,177 | 1,882 | 2,751 | 3,147 | 1,564 | 673 | 3 |
|---|
| Purchase of in-process research and development | - | - | - | 69 | 110 | 9 | 144 | 15 | 32 |
|---|
| Purchase of intangible assets | - | - | 1 | - | - | 43 | - | 19 | 5 |
|---|
| Purchase of long-term investments | - | - | - | - | - | 44 | 16 | 15 | 19 |
|---|
| Other investing activities | - | - | - | - | - | - | - | - | 3 |
|---|
| Net cash (used in) provided by investing activities | - | -356 | -638 | 554 | -3,168 | 641 | 1,077 | 60 | -548 |
|---|
| Proceeds from long-term loan | - | - | 42 | 67 | - | 17 | 37 | 23 | 9 |
|---|
| Repayment of long-term loan | - | - | 9 | 33 | - | - | - | 14 | 28 |
|---|
| Proceeds from Short-Term Debt | - | 2 | - | - | - | 406 | 314 | 662 | 868 |
|---|
| Repayment of short-term loans | - | 2 | - | - | - | 322 | 417 | 310 | 704 |
|---|
| Proceeds from option exercises and employee share purchase plan | - | - | - | - | 93 | 93 | 47 | 56 | 45 |
|---|
| Other financing activities | - | - | - | - | - | - | - | - | 3 |
|---|
| Net cash provided by (used in) financing activities | - | 490 | 1,691 | 86 | 5,203 | 3,637 | -19 | 416 | 193 |
|---|
| Effect of foreign exchange rate changes, net | - | - | - | - | 18 | 14 | -69 | -8 | -52 |
|---|
| Net decrease in cash, cash equivalents, and restricted cash | - | - | 501 | -120 | 769 | 2,993 | -508 | -689 | -547 |
|---|
| Income taxes paid | - | 29 | 12 | 9 | 11 | 16 | 30 | 56 | 69 |
|---|
| Interest paid | - | - | - | - | - | - | - | - | 51 |
|---|
| Accruals for capital expenditures | 2 | 2 | 22 | 29 | 43 | 53 | 95 | 92 | 70 |
|---|
| Acquired In Process Research And Development But Not Yet Paid | - | - | - | - | - | 75 | - | 32 | 60 |
|---|